CPT® Code 86940

1. Indications

The screening for hemolysins and cold agglutinins is indicated in various clinical scenarios where blood transfusion is being considered. The following conditions may warrant this screening:

• Pre-Transfusion Testing This procedure is performed to ensure the safety of blood transfusions by identifying potential hemolytic reactions that could occur due to the presence of hemolysins or cold agglutinins in the blood product.
• History of Hemolytic Reactions Patients with a previous history of hemolytic transfusion reactions may require this screening to prevent recurrence during future transfusions.
• Autoimmune Hemolytic Anemia Individuals diagnosed with autoimmune hemolytic anemia may have elevated levels of hemolysins or cold agglutinins, necessitating this screening prior to transfusion.

2. Procedure

The procedure for screening blood for hemolysins and cold agglutinins involves several key steps to ensure accurate results. Each step is critical in the overall process of blood safety assessment.

• Step 1: Sample Collection A blood sample is collected from the patient or donor. This sample must be handled with care to prevent contamination and ensure the integrity of the test results.
• Step 2: Initial Screening The collected blood sample is subjected to an initial screening process where it is tested for the presence of hemolysins. This involves mixing the blood with specific reagents that can detect the antibodies responsible for hemolysis.
• Step 3: Cold Agglutinin Testing Following the initial screening, the sample is then tested for cold agglutinins. This step may involve incubating the sample at lower temperatures to observe any agglutination of red blood cells, which indicates the presence of cold agglutinins.
• Step 4: Result Interpretation The results of the tests are interpreted by a qualified laboratory professional. If hemolysins or cold agglutinins are detected, further action may be required to ensure patient safety during transfusion.

3. Post-Procedure

After the screening procedure is completed, the results are documented and communicated to the healthcare provider responsible for the patient's care. If hemolysins or cold agglutinins are detected, the healthcare provider may need to consider alternative blood products or additional testing to ensure compatibility. It is essential for the healthcare team to review the results thoroughly to prevent any potential transfusion reactions. Patients may be monitored for any signs of adverse reactions following a transfusion, especially if there is a history of hemolytic reactions or if the screening results indicate potential risks.